QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
QQQ   292.99 (+0.94%)
AAPL   143.29 (+0.20%)
MSFT   245.12 (+0.99%)
META   148.10 (+0.71%)
GOOGL   97.65 (+0.73%)
AMZN   103.15 (+2.59%)
TSLA   173.23 (+3.94%)
NVDA   196.14 (+2.36%)
NIO   12.28 (+2.16%)
BABA   111.47 (+0.24%)
AMD   74.29 (+2.54%)
T   20.26 (+0.50%)
MU   60.19 (-2.46%)
F   13.34 (+3.49%)
CGC   2.93 (+3.17%)
GE   80.60 (-0.28%)
DIS   108.24 (+0.60%)
AMC   5.18 (+3.39%)
PFE   43.35 (-0.46%)
PYPL   80.67 (+1.29%)
NFLX   354.04 (+0.26%)
NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$13.98
+0.81 (+6.15%)
(As of 01/31/2023 11:12 AM ET)
Add
Compare
Today's Range
$13.55
$14.33
50-Day Range
$11.23
$16.00
52-Week Range
$10.41
$19.93
Volume
102,620 shs
Average Volume
737,006 shs
Market Capitalization
$935.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.40

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.6% Upside
$31.17 Price Target
Short Interest
Bearish
9.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.80mentions of Kura Oncology in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.12) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

749th out of 1,055 stocks

Pharmaceutical Preparations Industry

377th out of 518 stocks


KURA stock logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

Kura Oncology (NASDAQ:KURA) Trading Up 4.5%
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Kura Wins FDA Clearance for Tumor Treatment
H.C. Wainwright Keeps Their Buy Rating on Kura Oncology (KURA)
Cramer Is Holding This Biotech Stock
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Circling Back On Kura Oncology
Recap: Kura Oncology Q3 Earnings
Preview: Kura Oncology's Earnings
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.17
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+131.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-130,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.61 per share

Miscellaneous

Free Float
63,285,000
Market Cap
$935.26 million
Optionable
Optionable
Beta
0.90

Key Executives

  • Troy E. Wilson
    Chairman, President, CEO & Chief Financial Officer
  • Kathleen Ford
    Chief Operating Officer
  • Mollie Leoni
    Senior Vice President-Clinical Development
  • Stephen Dale
    Chief Medical Officer
  • Blake Tomkinson
    Vice President-Clinical Development













KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2023?

6 brokers have issued 12-month price objectives for Kura Oncology's stock. Their KURA share price forecasts range from $25.00 to $40.00. On average, they anticipate the company's stock price to reach $31.17 in the next twelve months. This suggests a possible upside of 136.6% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2023?

Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA stock has increased by 6.1% and is now trading at $13.17.
View the best growth stocks for 2023 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.04.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.72%), Hennion & Walsh Asset Management Inc. (0.08%), Dupont Capital Management Corp (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $13.17.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $881.07 million. The company earns $-130,470,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Kura Oncology have?

The company employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 1/31/2023 by MarketBeat.com Staff